Clinical Trials

Tue, 08/06/2021 - 07:30
London, UK, 8th June 2021 / Sciad Newswire / Inspired by the success of the inaugural MedTech Integrates last October,
Tue, 04/05/2021 - 06:30
Cambridge, MA, USA and Louvain-la-Neuve, Belgium, 4th May 2021 / Sciad Newswire / N-SIDE, a clinical trial su
Tue, 13/04/2021 - 07:30
York, UK, 13th April 2021 / Sciad Newswire / Antibiotic Research UK (ANTRUK), the world’s first charity tackl
Tristan Perotin, Responsable des Services Clients, G&L Scientific
Tue, 09/02/2021 - 07:30
London, UK, 9 février 2021 / Sciad Newswire / Les experts en affaires réglementaires, G&L Scientific, s
Tristan Perotin, Responsabile del Servizio Clienti, G&L Scientific
Tue, 09/02/2021 - 07:30
London, UK, 9 febbraio 2021 / Sciad Newswire / Esperta in Affari Regolatori, la G&L Scientific è lieta
Tue, 09/02/2021 - 07:30
London, UK, 9.
G&L Scientific en Espana
Wed, 03/02/2021 - 07:30
Barcelona, Spain, 3rd February 2021 / Sciad Newswire / G&L Scientific, consultora multinacional líder en Asuntos Regulat
COVID-19 Vaccine
Mon, 23/11/2020 - 14:00
Santa Clara, CA, USA, 23rd November 2020 / Sciad Newswire / Roambee’s technology solution for real-time logistics visibilit
Thu, 17/09/2020 - 12:00
The Huntington Study Group (“HSG”), a world leader in clinical research for Huntington’s Disease (HD), announces a partnership with Prilenia Therapeutics, a clinical stage biotech company led by Michael R. Hayden, MD, PhD, to conduct PRidopidine Outcome On Function in Huntington’s Disease (PROOF-HD) clinical study. PROOF-HD is a global Phase 3, randomized, double-blind, placebo-controlled, parallel arm, multicenter study evaluating the efficacy and safety of pridopidine in patients with early stage HD.
Mon, 14/09/2020 - 13:00
London, UK, 14th September 2020 / Sciad Newswire / WEP Group Holdings Limited (WEP), a specialist CRO focused on delive

Pages